AstraZeneca to acquire Amolyt Pharma for up to $1.05bn
Betsy Goodfellow | March 14, 2024 | News story | Business Services | Amolyt Pharma, AstraZeneca, Rare Diseases, acquisition, rare diseases
AstraZeneca has announced that it has entered into a definitive agreement under which it will acquire Amolyt Pharma for up to $1.05bn, with the focus on adding to AstraZeneca’s Alexion’s rare diseases pipeline.
The acquisition is intended to expand Alexion’s late-stage rare disease pipeline as well as its bone metabolism franchise, including the addition of eneboparatide, which is a phase 3 ‘investigational therapeutic peptide with a novel mechanism of action designed to meet key therapeutic goals for hypoparathyroidism’, according to the company’s press release.
It is expected that Alexion will also welcome a number of staff from Amolyt Pharma.
Marc Dunoyer, chief executive officer of Alexion, AstraZeneca Rare Disease, commented: “Chronic hypoparathyroid patients face a significant need for an alternative to current supportive therapies, which do not address the underlying hormone deficiency. As leaders in rare disease, Alexion is uniquely positioned to drive the late-stage development and global commercialisation of eneboparatide, which has the potential to lessen the often debilitating impact of low parathyroid hormone and avoid the risks of high-dose calcium supplementation. We believe this programme, together with Amolyt’s talented team, expertise and earlier pipeline, will enable our expansion into rare endocrinology.”
Thierry Abribat, chief executive officer of Amolyt Pharma, added: “We enthusiastically welcome the proposed acquisition of Amolyt by AstraZeneca, an organisation that shares our dedication to delivering life-changing treatments to people living with rare diseases. This agreement offers the opportunity to meaningfully advance our pipeline therapies. Strong phase 2 data suggests eneboparatide has the potential to improve outcomes for patients and to shift the treatment paradigm for hypoparathyroidism, and we look forward to seeing the continued advancement of the phase 3 trial.”
Betsy Goodfellow
Related Content
AstraZeneca’s Trixeo approved in EU for asthma
AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved in the European Union as a …
Phoenix Labs acquires Kent Pharma
Phoenix Labs has acquired UK pharmaceutical distributor Kent Pharma from private equity firm Duke Street, …
Samsung Biologics launches bid to acquire peptide CDMO PolyPeptide
Samsung Biologics has launched an all-cash public tender offer to acquire PolyPeptide Group in a …
